Congress Asset Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-89,557
Closed -$305K 392
2024
Q3
$305K Sell
89,557
-939
-1% -$4.09K ﹤0.01% 345
2024
Q2
$423K Sell
90,496
-1,135
-1% -$6.4K ﹤0.01% 340
2024
Q1
$680K Buy
91,631
+1,192
+1% +$9.9K ﹤0.01% 312
2023
Q4
$916K Buy
90,439
+205
+0.2% +$1.8K 0.01% 320
2023
Q3
$704K Buy
90,234
+120
+0.1% +$1.03K 0.01% 325
2023
Q2
$742K Buy
90,114
+565
+0.6% +$4.92K 0.01% 319
2023
Q1
$649K Buy
89,549
+8,842
+11% +$78.6K 0.01% 318
2022
Q4
$716K Buy
80,707
+638
+0.8% +$7K 0.01% 321
2022
Q3
$980K Buy
80,069
+1,004
+1% +$15.6K 0.01% 306
2022
Q2
$935K Buy
79,065
+622
+0.8% +$8.33K 0.01% 317
2022
Q1
$1.49M Buy
78,443
+7,667
+11% +$143K 0.01% 302
2021
Q4
$1.88M Buy
70,776
+21
+0% +$723 0.01% 287
2021
Q3
$2.91M Buy
70,755
+2,675
+4% +$147K 0.02% 249
2021
Q2
$3.86M Buy
68,080
+10,440
+18% +$386K 0.03% 234
2021
Q1
$2.42M Buy
+57,640
New +$3.28M 0.02% 250

Other funds holding EDIT

Congress Asset Management's EDIT Position: Q4 2024 in Review

Congress Asset Management sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 89,557 shares — an estimated $305K sold.

Congress Asset Management first reported a position in EDIT in Q1 2021 and held it in 15 quarters. The position peaked at $3.86M in Q2 2021. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • Congress Asset Management reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • Congress Asset Management sold 89,557 Editas Medicine shares in Q4 2024, an estimated $305K.
  • Congress Asset Management first reported a position in Editas Medicine in Q1 2021 and held it in 15 quarters.
  • Congress Asset Management's Editas Medicine position peaked at $3.86M in Q2 2021.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Congress Asset Management's 13F filing for Q4 2024, filed 30 Jan 2025.